- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00604422
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis
연구 개요
상세 설명
Ulcerative colitis (UC) is a disorder of unknown origin that may be characterized by acute and chronic inflammation of the colon. The extent of the colonic mucosal inflammation varies among individuals, but the disease almost always involves the rectum. Ulcerative colitis has required evaluation by colonoscopy to determine the extent and severity of the disease. The PillCam platform offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, a swallowable device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the PillCam platform include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the PillCam platform may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon.
The PillCam® SB capsule (formerly M2A® Capsule) that was FDA-approved in August 2001 for small bowel evaluation has been ingested to date by more than 700,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. Further details of the PillCam® Colon Capsule Endoscope (PCCE) can be found in the device description section.
In previous studies, the PillCam colon platform has been shown to be safe and to be able to demonstrate colon polyps and cancers. This study is an extension to a trial evaluating the use of PCCE in ulcerative colitis that has already been completed in Hong Kong (n=40). This study is designed to assess the ability of the capsule to accurately detect inflammatory lesions and thus classifying the extent and severity of disease in subjects with ulcerative colitis in comparison to traditional colonoscopy.
연구 유형
등록 (실제)
연락처 및 위치
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
The study population will consist of subjects who fulfill all the inclusion criteria and none of the exclusion criteria.
설명
Inclusion Criteria:
- Subjects 18-70
- Suspected or known ulcerative colitis patients
Exclusion Criteria:
- Subject has dysphagia
- Subject has congestive heart failure
- Subject who can not tolerate bowel preparation
- Poor bowel preparation
- Subject has renal insufficiency
- Subject is known or is suspected to suffer from intestinal obstruction.
- Subject has a cardiac pacemaker or other implanted electro-medical devices.
- Subject is pregnant
- Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
- Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
- Subject has any condition, which precludes compliance with study and/or device instructions.
- Subject suffers from life threatening conditions
- Subject is currently participating in another clinical study
- Subject has constipation (less than 3 bowel movements/week)
- Subject has known slow gastric emptying time
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
A
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Agreement level between capsule and colonoscopy in classifying colitis into the above (see section 3.1) categories.
기간: within 7 days
|
within 7 days
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number, type and severity of adverse events with both PCCE and standard colonoscopy
기간: Within 7 days
|
Within 7 days
|
|
Accuracy parameters for detecting active UC
기간: within 7 days
|
within 7 days
|
|
Disease severity scoring index for both PCCE and .standard colonoscopy
기간: within 7 days
|
within 7 days
|
|
Colon cleansing level score for both PCCE and standard colonoscopy.
기간: within 7 days
|
within 7 days
|
|
Grading of the bubbles interference at the colon for PCCE.
기간: Within 7 days
|
Within 7 days
|
|
Percentage of excreted colon capsules
기간: Within 7 Days
|
Within 7 Days
|
|
PCCE transit time from ingestion to excretion and colon transit time
기간: Within 7 Days
|
Within 7 Days
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Josef Sung, Prof., Chinese University of Hong Kong
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .